Haemair was founded in 2005 by engineers with close relatives who had suffered and died of lung disease.

From the outset, the vision was of a device that would directly oxygenate blood to augment residual lung capacity and ultimately provide an alternative to lung transplant.

The company has attracted investment of over £3million from a core group who hope ultimately to gain a return on their investment, but whose primary motivation is to help lung-disease sufferers and their families.

The Company moved to the Swansea University site in 2006 in order to benefit from the world-leading research in blood rheology coming from the collaboration between the Engineering and Medical Schools.

We have succeeded in recruiting a young talented team of scientists and engineers who share our vision.

Our innovative technology recognised by both the Welsh and UK Governments to the extent that we have received R&D grants in excess of £2million.

We have shown that we can build a manufacturing facility capable of producing devices in numbers